181 related articles for article (PubMed ID: 16399769)
1. Lifetime effects, costs, and cost effectiveness of testing for human papillomavirus to manage low grade cytological abnormalities: results of the NHS pilot studies.
Legood R; Gray A; Wolstenholme J; Moss S
BMJ; 2006 Jan; 332(7533):79-85. PubMed ID: 16399769
[TBL] [Abstract][Full Text] [Related]
2. Effect of testing for human papillomavirus as a triage during screening for cervical cancer: observational before and after study.
Moss S; Gray A; Legood R; Vessey M; Patnick J; Kitchener H;
BMJ; 2006 Jan; 332(7533):83-5. PubMed ID: 16399706
[TBL] [Abstract][Full Text] [Related]
3. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance.
Kim JJ; Wright TC; Goldie SJ
JAMA; 2002 May; 287(18):2382-90. PubMed ID: 11988059
[TBL] [Abstract][Full Text] [Related]
5. Costs and benefits of different strategies to screen for cervical cancer in less-developed countries.
Mandelblatt JS; Lawrence WF; Gaffikin L; Limpahayom KK; Lumbiganon P; Warakamin S; King J; Yi B; Ringers P; Blumenthal PD
J Natl Cancer Inst; 2002 Oct; 94(19):1469-83. PubMed ID: 12359856
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of high-risk human papillomavirus testing for cervical cancer screening in Québec, Canada.
Vijayaraghavan A; Efrusy MB; Mayrand MH; Santas CC; Goggin P
Can J Public Health; 2010; 101(3):220-5. PubMed ID: 20737813
[TBL] [Abstract][Full Text] [Related]
7. Psychological impact of human papillomavirus testing in women with borderline or mildly dyskaryotic cervical smear test results: cross sectional questionnaire study.
Maissi E; Marteau TM; Hankins M; Moss S; Legood R; Gray A
BMJ; 2004 May; 328(7451):1293. PubMed ID: 15166066
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy.
Kim JJ; Wright TC; Goldie SJ
J Natl Cancer Inst; 2005 Jun; 97(12):888-95. PubMed ID: 15956650
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more.
Goldie SJ; Kim JJ; Wright TC
Obstet Gynecol; 2004 Apr; 103(4):619-31. PubMed ID: 15051550
[TBL] [Abstract][Full Text] [Related]
10. Optimal Management Strategies for Primary HPV Testing for Cervical Screening: Cost-Effectiveness Evaluation for the National Cervical Screening Program in Australia.
Simms KT; Hall M; Smith MA; Lew JB; Hughes S; Yuill S; Hammond I; Saville M; Canfell K
PLoS One; 2017; 12(1):e0163509. PubMed ID: 28095411
[TBL] [Abstract][Full Text] [Related]
11. Economic analysis of human papillomavirus triage, repeat cytology, and immediate colposcopy in management of women with minor cytological abnormalities in Sweden.
Ostensson E; Fröberg M; Hjerpe A; Zethraeus N; Andersson S
Acta Obstet Gynecol Scand; 2010 Oct; 89(10):1316-25. PubMed ID: 20846064
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of cervical cancer screening: cytology versus human papillomavirus DNA testing.
van Rosmalen J; de Kok IM; van Ballegooijen M
BJOG; 2012 May; 119(6):699-709. PubMed ID: 22251259
[TBL] [Abstract][Full Text] [Related]
13. Benefits and costs of using HPV testing to screen for cervical cancer.
Mandelblatt JS; Lawrence WF; Womack SM; Jacobson D; Yi B; Hwang YT; Gold K; Barter J; Shah K
JAMA; 2002 May; 287(18):2372-81. PubMed ID: 11988058
[TBL] [Abstract][Full Text] [Related]
14. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs.
Kulasingam SL; Myers ER
JAMA; 2003 Aug; 290(6):781-9. PubMed ID: 12915431
[TBL] [Abstract][Full Text] [Related]
15. Cost effectiveness of human papillomavirus testing to augment cervical cancer screening in women infected with the human immunodeficiency virus.
Goldie SJ; Freedberg KA; Weinstein MC; Wright TC; Kuntz KM
Am J Med; 2001 Aug; 111(2):140-9. PubMed ID: 11498068
[TBL] [Abstract][Full Text] [Related]
16. Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial.
Ronco G; Segnan N; Giorgi-Rossi P; Zappa M; Casadei GP; Carozzi F; Dalla Palma P; Del Mistro A; Folicaldi S; Gillio-Tos A; Nardo G; Naldoni C; Schincaglia P; Zorzi M; Confortini M; Cuzick J;
J Natl Cancer Inst; 2006 Jun; 98(11):765-74. PubMed ID: 16757701
[TBL] [Abstract][Full Text] [Related]
17. [Health technology assessment report. Use of liquid-based cytology for cervical cancer precursors screening].
Ronco G; Confortini M; Maccallini V; Naldoni C; Segnan N; Sideri M; Zappa M; Zorzi M; Calvia M; Giorgi Rossi P
Epidemiol Prev; 2012; 36(5 Suppl 2):e1-e33. PubMed ID: 23139163
[TBL] [Abstract][Full Text] [Related]
18. Cross sectional study of conventional cervical smear, monolayer cytology, and human papillomavirus DNA testing for cervical cancer screening.
Coste J; Cochand-Priollet B; de Cremoux P; Le Galès C; Cartier I; Molinié V; Labbé S; Vacher-Lavenu MC; Vielh P;
BMJ; 2003 Apr; 326(7392):733. PubMed ID: 12676841
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of cervical screening strategies with adjunct high-risk human papillomavirus testing for women with borderline or mild dyskaryosis.
Berkhof J; de Bruijne MC; Zielinski GD; Bulkmans NW; Rozendaal L; Snijders PJ; Verheijen RH; Meijer CJ
Int J Cancer; 2006 Apr; 118(7):1759-68. PubMed ID: 16217759
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of human papillomavirus vaccination and screening in Spain.
Diaz M; de Sanjose S; Ortendahl J; O'Shea M; Goldie SJ; Bosch FX; Kim JJ
Eur J Cancer; 2010 Nov; 46(16):2973-85. PubMed ID: 20638840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
